NovoCure Ltd. (NVCR) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1241956,
    "name": "NovoCure Ltd.",
    "stock_name": "NovoCure Ltd.",
    "full_name": "NovoCure Ltd.",
    "name_url": "stocks-analysis/novocure",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "11.76",
    "chg": 0.84,
    "chgp": "7.69%",
    "dir": 1,
    "prev_price": "10.92",
    "mcapval": "1,408.67",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2325,
    "indexname": "S&P 500",
    "isin": "JE00BYSS4X48",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "3.57 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/novocure-1241956-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "NovoCure Ltd. Hits Day High with Strong 7.67% Intraday Surge",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/novocure-ltd-hits-day-high-with-strong-767-intraday-surge-3626729",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/NovoCure_priceRelatedfactors_3626729.png",
        "date": "2025-10-16 19:01:35",
        "description": "NovoCure Ltd. has seen a significant increase in its stock price today, contrasting with a slight decline in the S&P 500. While the company has shown positive monthly performance, its long-term outlook remains challenging, with substantial declines over the past year and three years, alongside concerning financial metrics."
      },
      {
        "title": "Is NovoCure Ltd. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-novocure-ltd-technically-bullish-or-bearish-3546906",
        "imagepath": "",
        "date": "2025-09-20 19:42:47",
        "description": "As of 12 September 2025, the technical trend for NovoCure Ltd. has changed from mildly bearish to bearish. The weekly MACD is bearish, and the daily moving averages indicate a mildly bearish stance. Bollinger Bands are also showing a mildly bearish trend on both weekly and monthly time frames. The KST is bearish on a weekly basis, while the monthly remains mildly bullish, indicating some divergence. Overall, the Dow Theory shows no trend on a weekly basis and mildly bearish on a monthly basis.\n\nIn terms of performance, NovoCure has underperformed significantly compared to the S&P 500, with a year-to-date return of -56.38% versus the S&P 500's 12.22%, and a 3-year return of -85.05% compared to the S&P 500's 70.41%. This highlights a stark contrast in performance, reinforcing the bearish technical stance...."
      },
      {
        "title": "Is NovoCure Ltd. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-novocure-ltd-overvalued-or-undervalued-3543387",
        "imagepath": "",
        "date": "2025-09-20 18:18:04",
        "description": "As of 29 July 2021, the valuation grade for NovoCure Ltd. moved from fair to risky, indicating a more cautious outlook on the stock. The company appears to be overvalued given its high Price to Book Value of 5.24 and negative EV to EBIT and EV to EBITDA ratios of -9.77 and -10.51, respectively. Additionally, the Return on Capital Employed (ROCE) stands at a concerning -190.50%, further emphasizing the company's struggles.\n\nIn comparison to its peers, NovoCure's EV to EBITDA ratio of -7.2229 is significantly worse than that of TransMedics Group, which has a fair valuation with an EV to EBITDA of 37.0142. Other risky peers like iRhythm Technologies show an even more negative EV to EBITDA of -145.8167. The stock's performance has lagged behind the S&P 500, with a year-to-date return of -56.38% compared to the index's 12.22%, reinforcing the notion that NovoCure is currently overvalued...."
      },
      {
        "title": "NovoCure Ltd. Experiences Revision in Stock Evaluation Amid Market Dynamics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/novocure-ltd-technical-trend-shifts-from-mildly-bearish-to-bearish-amid-ongoing-challenges-3522885",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/NovoCure_technicaldot_3522885.png",
        "date": "2025-09-16 18:58:05",
        "description": "NovoCure Ltd., a small-cap pharmaceutical company, has experienced significant stock fluctuations, with a 52-week range between $10.87 and $34.13. Recent evaluations indicate mixed technical indicators, reflecting a cautious market outlook. Over the past year, the company's performance has lagged behind the S&P 500, highlighting ongoing challenges."
      }
    ],
    "total": 9,
    "sid": "1241956",
    "stock_news_url": "https://www.marketsmojo.com/news/novocure-1241956"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

NovoCure Ltd. Hits Day High with Strong 7.67% Intraday Surge

2025-10-16 19:01:35

NovoCure Ltd. has seen a significant increase in its stock price today, contrasting with a slight decline in the S&P 500. While the company has shown positive monthly performance, its long-term outlook remains challenging, with substantial declines over the past year and three years, alongside concerning financial metrics.

Is NovoCure Ltd. technically bullish or bearish?

2025-09-20 19:42:47

As of 12 September 2025, the technical trend for NovoCure Ltd. has changed from mildly bearish to bearish. The weekly MACD is bearish, and the daily moving averages indicate a mildly bearish stance. Bollinger Bands are also showing a mildly bearish trend on both weekly and monthly time frames. The KST is bearish on a weekly basis, while the monthly remains mildly bullish, indicating some divergence. Overall, the Dow Theory shows no trend on a weekly basis and mildly bearish on a monthly basis. In terms of performance, NovoCure has underperformed significantly compared to the S&P 500, with a year-to-date return of -56.38% versus the S&P 500's 12.22%, and a 3-year return of -85.05% compared to the S&P 500's 70.41%. This highlights a stark contrast in performance, reinforcing the bearish technical stance....

Is NovoCure Ltd. overvalued or undervalued?

2025-09-20 18:18:04

As of 29 July 2021, the valuation grade for NovoCure Ltd. moved from fair to risky, indicating a more cautious outlook on the stock. The company appears to be overvalued given its high Price to Book Value of 5.24 and negative EV to EBIT and EV to EBITDA ratios of -9.77 and -10.51, respectively. Additionally, the Return on Capital Employed (ROCE) stands at a concerning -190.50%, further emphasizing the company's struggles. In comparison to its peers, NovoCure's EV to EBITDA ratio of -7.2229 is significantly worse than that of TransMedics Group, which has a fair valuation with an EV to EBITDA of 37.0142. Other risky peers like iRhythm Technologies show an even more negative EV to EBITDA of -145.8167. The stock's performance has lagged behind the S&P 500, with a year-to-date return of -56.38% compared to the index's 12.22%, reinforcing the notion that NovoCure is currently overvalued....

NovoCure Ltd. Experiences Revision in Stock Evaluation Amid Market Dynamics

2025-09-16 18:58:05

NovoCure Ltd., a small-cap pharmaceutical company, has experienced significant stock fluctuations, with a 52-week range between $10.87 and $34.13. Recent evaluations indicate mixed technical indicators, reflecting a cautious market outlook. Over the past year, the company's performance has lagged behind the S&P 500, highlighting ongoing challenges.

View All News